Ovid Therapeutics (OVID) Other Non-Current Assets (2016 - 2026)

Ovid Therapeutics' Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• Quarterly Other Non-Current Assets rose 4851.28% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 4851.28% YoY) and the FY2025 annual result came in at $1.9 million, changed 0.0% from the prior year.
• Other Non-Current Assets was $1.9 million for Q1 2026 at Ovid Therapeutics, roughly flat from $1.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.9 million in Q4 2023 and bottomed at $39000.0 in Q1 2025.
• A 5-year average of $1.2 million and a median of $1.9 million in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets sank 90.57% — and 2026, when it surged 4851.28%.
• Ovid Therapeutics' Other Non-Current Assets stood at $1.9 million in 2022, then rose by 0.01% to $1.9 million in 2023, then changed by 0.0% to $1.9 million in 2024, then changed by 0.0% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
• Business Quant data shows OVID's Other Non-Current Assets at $1.9 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.